Pharmacogenetics of response to neoadjuvant paclitaxel treatment for locally advanced breast cancer

Locally advanced breast cancer (LABC) cases have a varying five-year survival rate, mainly influenced by the tumor response to chemotherapy. Paclitaxel activity (response rate) varies across populations from 21.5% to 84%. There are some reports on genetic traits and paclitaxel; however, there is sti...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez-Ortiz, Andric C., Ramírez, Israel, Cruz-López, Juan C., Villarreal-Garza, Cynthia, Luna-Angulo, Alexandra, Lira-Romero, Esmeralda, Jiménez-Chaidez, Salvador, Díaz-Chávez, José, Matus-Santos, Juan A., Sánchez-Chapul, Laura, Mendoza-Lorenzo, Patricia, Estrada-Mena, Francisco J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739747/
https://www.ncbi.nlm.nih.gov/pubmed/29290962
http://dx.doi.org/10.18632/oncotarget.22461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739747/
https://www.ncbi.nlm.nih.gov/pubmed/29290962
http://dx.doi.org/10.18632/oncotarget.22461

Ejemplares similares